Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
PZ HTL SA

Canada to Develop New Isotope Production Methods

By BiotechDaily International staff writers
Posted on 11 Mar 2013
An aging reactor and a worldwide looming shortage of medical isotopes has driven Canada to search for alternatives methods to manufacture technetium-99m (99mTc).

At the moment, Canada's only source of the isotope is the National Research Universal (NRU; Chalk River, Ontario, Canada) reactor at Chalk River Laboratories (CRL, Ontario, Canada), which produces about a third of the world's supply. But the reactor has been plagued with safety and operational problems, leading to worldwide shortages, and its license is set to expire in 2016. Consequently, Canada is investing close to USD 21 million in three projects in western Canada that have demonstrated the ability to produce the key medical isotope without a nuclear reactor.

Two of the research institutes, the national laboratory for particle and nuclear physics (TRIUMF; Vancouver, BC, Canada) and the University of Alberta (Edmonton, Canada) are using cyclotron technology to produce the isotope, while the third, Prairie Isotope Production Enterprise (PIPE; Pinawa, MB, Canada), is using a linear accelerator.

In the cyclotron process, the machine bombards a target of molybdenum-100 with high-energy protons, converting some of its atoms to molybdenum-99 (Mo-99). Then chemical processing removes technetium-99 from the target, ready for use. The PIPE technology uses an electron accelerator rather than a nuclear reactor to make the Mo-99. The electron accelerator sprays electricity onto molybdenum metal, which produces the Mo-99 radioisotope. Next, a chemical process is used to fabricate the Tc-99m.

“The Harper Government is investing in Canadian expertise to help ensure new sources of supply for medical isotopes used in diagnosing various diseases, such as cancer and heart disease,” said Joe Oliver Canada’s natural resources minister. “We are investing in the work needed to attract private sector interest and to bring new technologies to market, and to help ensure that isotope production is on a sound commercial footing.”

Tc-99m is obtained from the decay of its parent isotope Mo-99 compounds that are packed into nuclear "generators" and distributed to hospitals, where nuclear medicine specialists can draw off the Tc-99m as needed for about a week. Tc-99m is used in 80% of nuclear medicine diagnostic procedures in Canada, and about 85% of all medical imaging procedures worldwide. It is currently made in reactors in Canada, the Netherlands, Belgium, France, Australia, and South Africa.

Related Links:

National Research Universal
TRIUMF
Prairie Isotope Production Enterprise



Channels

Genomics/Proteomics

view channel
Image: The TheraCyte cell encapsulation device (Photo courtesy of TheraCyte, Inc.).

Encapsulated Human-Insulin-Producing Progenitor Cells Cure Diabetes in Mouse Model

A breakthrough system that allows subcutaneous implantation of encapsulated immature pancreatic cells (beta progenitor cells) was shown to produce enough insulin to correct the symptoms of diabetes in a mouse model.... Read more

Drug Discovery

view channel
Image: Chitosan is derived from the shells of shrimp and other sea crustaceans, including Alaskan pink shrimp, pictured here (Photo courtesy of NOAA - [US] National Oceanic and Atmospheric Administration).

Chitosan Treatment Clears the Way for Antibiotics to Eliminate Recurrent Urinary Tract Infections

Recurrent urinary tract infection was successfully resolved in a mouse model by treatment with the exfoliant chitosan followed by a round of antibiotics. Bacterial urinary tract infection (UTI), most... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more

Business

view channel

Analytical Sciences Trade Fair Declared a Rousing Success

Organizers of this year's 24th "analytica" biosciences trade fair have reported significant increases in both the number of visitors and exhibitors compared to the 2012 event. The analytica trade fair for laboratory technology, analysis, and biotechnology has been held at the Munich (Germany) Trade Fair Center every... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.